Yulia Maxuitenko

1.1k total citations
46 papers, 775 citations indexed

About

Yulia Maxuitenko is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Yulia Maxuitenko has authored 46 papers receiving a total of 775 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 19 papers in Oncology and 11 papers in Pharmacology. Recurrent topics in Yulia Maxuitenko's work include Inflammatory mediators and NSAID effects (8 papers), Synthesis and biological activity (6 papers) and Peptidase Inhibition and Analysis (6 papers). Yulia Maxuitenko is often cited by papers focused on Inflammatory mediators and NSAID effects (8 papers), Synthesis and biological activity (6 papers) and Peptidase Inhibition and Analysis (6 papers). Yulia Maxuitenko collaborates with scholars based in United States, United Kingdom and Germany. Yulia Maxuitenko's co-authors include Gary A. Piazza, Adam B. Keeton, Bill D. Roebuck, Thomas W. Kensler, Yonghe Li, Heather N. Tinsley, Bernard D. Gary, Jose Thaiparambil, Lisa P. Jacobson and John D. Groopman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Yulia Maxuitenko

41 papers receiving 756 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yulia Maxuitenko United States 16 479 179 143 122 119 46 775
Véronique Bourgarel‐Rey France 22 526 1.1× 277 1.5× 104 0.7× 247 2.0× 152 1.3× 30 1.1k
Alex Philchenkov Ukraine 14 451 0.9× 123 0.7× 84 0.6× 175 1.4× 75 0.6× 39 812
Michelle Helen Visagie South Africa 15 401 0.8× 120 0.7× 41 0.3× 110 0.9× 185 1.6× 33 698
Olivia Aranha United States 13 398 0.8× 213 1.2× 70 0.5× 129 1.1× 76 0.6× 34 676
Stephen P. Fink United States 17 646 1.3× 256 1.4× 163 1.1× 46 0.4× 292 2.5× 31 1.1k
Olesya A. Ulanovskaya United States 15 636 1.3× 134 0.7× 67 0.5× 233 1.9× 139 1.2× 18 925
Swayamsiddha Kar India 18 635 1.3× 126 0.7× 40 0.3× 93 0.8× 168 1.4× 38 901
Wen‐Ying Liao Taiwan 15 431 0.9× 238 1.3× 124 0.9× 41 0.3× 149 1.3× 23 757
Brian D. Koh United States 12 702 1.5× 218 1.2× 63 0.4× 81 0.7× 291 2.4× 17 942

Countries citing papers authored by Yulia Maxuitenko

Since Specialization
Citations

This map shows the geographic impact of Yulia Maxuitenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yulia Maxuitenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yulia Maxuitenko more than expected).

Fields of papers citing papers by Yulia Maxuitenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yulia Maxuitenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yulia Maxuitenko. The network helps show where Yulia Maxuitenko may publish in the future.

Co-authorship network of co-authors of Yulia Maxuitenko

This figure shows the co-authorship network connecting the top 25 collaborators of Yulia Maxuitenko. A scholar is included among the top collaborators of Yulia Maxuitenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yulia Maxuitenko. Yulia Maxuitenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Piazza, Gary A., Jeremy B. Foote, Adam B. Keeton, et al.. (2024). A potent and selective pan-RAS inhibitor, ADT-1004, targeting complex KRAS mutations for pancreatic cancer.. Journal of Clinical Oncology. 42(23_suppl). 90–90. 1 indexed citations
2.
Piazza, Gary A., Jeremy B. Foote, Adam B. Keeton, et al.. (2024). A potent and selective pan-RAS inhibitor, ADT-1004, targeting complex KRAS mutations for pancreatic cancer.. Journal of Clinical Oncology. 42(16_suppl). e15085–e15085.
3.
Maxuitenko, Yulia, Jeremy B. Foote, Adam B. Keeton, et al.. (2024). Abstract 5915: ADT-1004: A promising pan-RAS inhibitor for targeting KRAS mutations in pancreatic ductal adenocarcinoma. Cancer Research. 84(6_Supplement). 5915–5915. 2 indexed citations
4.
Foote, Jeremy B., Adam B. Keeton, Yulia Maxuitenko, et al.. (2023). Abstract 4140: Oncogenic KRAS inhibition with ADT-007 primes T cell responses in pancreatic ductal adenocarcinoma. Cancer Research. 83(7_Supplement). 4140–4140. 2 indexed citations
5.
Tinsley, Heather N., Bini Mathew, Yulia Maxuitenko, et al.. (2023). Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats. Cancers. 15(3). 646–646. 5 indexed citations
6.
7.
8.
Abdel‐Halim, Mohammad, Amr Hefnawy, Ahmed Maher, et al.. (2021). From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity. Journal of Medicinal Chemistry. 64(8). 4462–4477. 19 indexed citations
9.
Piazza, Gary A., Xi Chen, Yulia Maxuitenko, et al.. (2020). PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity. Drug Discovery Today. 25(8). 1521–1527. 51 indexed citations
10.
11.
Adamska, Aleksandra, Alice Domenichini, Emily Capone, et al.. (2019). Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. Journal of Experimental & Clinical Cancer Research. 38(1). 312–312. 21 indexed citations
12.
Thottassery, Jaideep V., Paula W. Allan, Joseph A. Maddry, et al.. (2014). Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4′-thio-2′-deoxycytidine and 5-aza-4′-thio-2′-deoxycytidine. Cancer Chemotherapy and Pharmacology. 74(2). 291–302. 53 indexed citations
13.
Karmali, Rashida A., Yulia Maxuitenko, Greg Gorman, & Zhican Qu. (2012). Combinatorial treatment with carboxyamidotriazole- orotate and temozolomide in sc-implanted human LOX IMVI melanoma xenografts. 2(5). 4 indexed citations
14.
Bhatia, Shilpa, Benjamin D.�L. Li, Xiao Lin Li, et al.. (2011). Establishment of a mammary carcinoma cell line from Syrian hamsters treated with N-methyl-N-nitrosourea. Cancer Letters. 312(1). 82–90. 6 indexed citations
15.
Carter, Christopher A., Charles Chen, Patrick W. Vincent, et al.. (2006). Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemotherapy and Pharmacology. 59(2). 183–195. 70 indexed citations
16.
Maxuitenko, Yulia, John J. Rinehart, William R. Waud, et al.. (2005). A preclinical study of tamoxifen in combination with bevacizumab (Avastin) for the treatment of ER-positive breast cancer. Cancer Research. 65. 254–254.
17.
Frydman, Benjamín, Carl W. Porter, Yulia Maxuitenko, et al.. (2003). A novel polyamine analog (SL-11093) inhibits growth of human prostate tumor xenografts in nude mice. Cancer Chemotherapy and Pharmacology. 51(6). 488–492. 35 indexed citations
18.
Maxuitenko, Yulia. (1998). Identification of dithiolethiones with better chemopreventive properties than oltipraz. Carcinogenesis. 19(9). 1609–1615. 63 indexed citations
19.
Maxuitenko, Yulia, William G. North, & Bill D. Roebuck. (1997). Urinary taurine as a non-invasive marker of aflatoxin B1-induced hepatotoxicity: success and failure. Toxicology. 118(2-3). 159–169. 8 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Véronique Bourgarel‐Rey Breakdown of academic impact, for papers by Alex Philchenkov Breakdown of academic impact, for papers by Michelle Helen Visagie Breakdown of academic impact, for papers by Olivia Aranha Breakdown of academic impact, for papers by Stephen P. Fink Breakdown of academic impact, for papers by Olesya A. Ulanovskaya Breakdown of academic impact, for papers by Swayamsiddha Kar Breakdown of academic impact, for papers by Wen‐Ying Liao Breakdown of academic impact, for papers by Brian D. Koh
Rankless by CCL
2026